Abstract
The coronavirus infection caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may be related with a wide range of disease and ranging from mild to life-threatening pneumonia. Patients with COVID-19 have higher susceptibility to fungal coinfections. Mucormycosis is a rare and-threatening fungal infection. Mucormycosis is more common in immunocompromised individuals, and patients with uncontrolled diabetes. COVID-19 associated mucormycosis usually developed 10-14 days after hospitalization. A high number of suspicion diagnosis and aggressive management is required to improve outcomes of the therapy. Awareness of warning symptoms and signs play an important role for the identification of the mucormycosis.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
